Anastrozole Side Effects
Anastrozole causes several important side effects that require monitoring and patient counseling, with the most clinically significant being bone loss/fractures, musculoskeletal symptoms (joint pain, stiffness, arthralgia), vasomotor symptoms (hot flashes), and cardiovascular effects. 1, 2
Most Common Side Effects (≥10% incidence)
The FDA-approved labeling and ASCO guidelines identify these frequent adverse reactions 2:
- Hot flashes (most common reason for discontinuation)
- Musculoskeletal effects: Joint aches, joint pain, stiffness, swelling (arthritis), arthralgia
- Weakness (asthenia)
- Hypertension
- Depression and mood disturbances
- Nausea and vomiting
- Rash
- Back pain and bone pain
- Insomnia
- Headache
- Peripheral edema (leg, ankle, or feet swelling)
- Increased cough and shortness of breath (dyspnea)
- Sore throat (pharyngitis)
- Lymphedema (in affected arm after breast cancer surgery)
Critical Side Effects Requiring Monitoring
Bone Health Complications
Bone thinning (osteoporosis) and increased fracture risk are major concerns with anastrozole, as it lowers estrogen levels that protect bone density. 1, 2
Management algorithm:
- Measure bone mineral density (BMD) before starting anastrozole
- Monitor BMD during treatment
- Use caution in patients with moderate bone loss
- Consider bisphosphonates or RANKL inhibitors for bone protection
- Contraindicated in severe osteoporosis (T-score < -4 or >2 vertebral fractures)
- All patients should: exercise regularly, take calcium and vitamin D supplements
The ATAC trial demonstrated mean decreases in both lumbar spine and total hip BMD compared to baseline, while tamoxifen increased BMD 2.
Cardiovascular Effects
Elevated cholesterol occurs with anastrozole; monitor lipid panels during treatment 2.
In women with pre-existing ischemic heart disease, anastrozole showed higher rates of ischemic cardiovascular events (17%) compared to tamoxifen (10%), including:
- Angina pectoris: 11.6% (anastrozole) vs 5.2% (tamoxifen)
- Myocardial infarction rates were actually lower with anastrozole (0.9% vs 3.2%) 2
In the overall population without pre-existing heart disease, cardiovascular event rates were similar between treatments (4% vs 3%).
Hepatotoxicity (Rare but Serious)
Liver inflammation and dysfunction can occur, requiring immediate discontinuation if symptoms develop 2, 3, 4:
Stop anastrozole immediately if:
- General feeling of being unwell
- Yellowing of skin or eyes (jaundice)
- Right upper abdominal pain
- Abnormal liver function tests
Case reports suggest increased risk after viral infections (including mild COVID-19) and in patients on multiple medications affecting hepatobiliary transport 3, 4.
Serious But Rare Side Effects (<1 in 10,000)
- Severe skin reactions: lesions, ulcers, blisters → stop drug immediately
- Severe allergic reactions: facial/lip/tongue/throat swelling, difficulty swallowing/breathing → seek emergency care
- Ocular complications: papilledema, macular edema, uveitis, retinopathy, corneal changes, blepharitis 5
Additional Notable Side Effects
- Neurological: Tingling, numbness of skin; memory impairment; somnolence 2, 6
- Mood disturbances: Depression, anxiety, fatigue (can be severe enough to require discontinuation) 6
- Vaginal dryness and problems 7, 2
- Dry eyes 1
- Gastrointestinal disturbances: More common than with megestrol (29-33%), usually mild and transient 8, 9
Important Clinical Pitfalls
Avoid these common errors:
Do NOT use in premenopausal women - anastrozole is only for postmenopausal women 1
Do NOT combine with tamoxifen - concurrent use lowers anastrozole blood levels and reduces efficacy 2
Do NOT use with estrogen-containing products - hormone replacement therapy, birth control pills, estrogen creams, vaginal rings, or suppositories will interfere with anastrozole's mechanism 2
Do NOT overlook baseline bone assessment - failure to check BMD before starting therapy misses opportunity for preventive intervention 1
Monitor patients with pre-existing heart disease more closely - they have substantially higher cardiovascular event rates 2
Quality of Life Considerations
The SOLE trial showed that compared to continuous letrozole, anastrozole patients experienced significantly more vaginal problems (8.8% vs 7.4%, p=0.017) and musculoskeletal pain (p=0.023), with worse sleep disturbance (p=0.0073), physical well-being (p=0.0080), and mood (p=0.026) 7.